Jade Biosciences (JBIO) Common Equity (2020 - 2026)

Jade Biosciences has reported Common Equity for 7 years, with the latest figure at $296.5 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 455.0% year-over-year to $296.5 million; the trailing twelve-month figure through Mar 2026 stood at $296.5 million (up 455.0% YoY), and the FY2025 full-year result was $332.5 million, up 810.52% from the prior year.
• Common Equity for Q1 2026 stood at $296.5 million, down from $332.5 million in the prior quarter.
• The five-year high for Common Equity was $332.5 million in Q4 2025, with the low at -$83.5 million in Q1 2025.
• Historically, Common Equity has averaged $118.9 million across 5 years, with a median of $126.7 million in 2022.
• The largest YoY upside for Common Equity was 34320.03% in 2025 against a maximum downside of 191.87% in 2025.
• Jade Biosciences' Common Equity stood at $126.7 million in 2022, then slipped by 13.64% to $109.5 million in 2023, then slumped by 142.76% to -$46.8 million in 2024, then soared by 810.52% to $332.5 million in 2025, then dropped by 10.84% to $296.5 million in 2026.
• The last three Common Equity figures came in at $296.5 million (Q1 2026), $332.5 million (Q4 2025), and $179.3 million (Q3 2025), per Business Quant data.